Testing a new vaccine for the Chikungunya virus
Official title: A Randomized Phase I Clinical Trial of HydroVax-CHIKV, a Novel Inactivated Chikungunya Virus Vaccine
Funded at Najit Technologies, INC. · NIH-11009620 · Data updated 2026-11-12
This study is testing a new vaccine called HydroVax-CHIKV to see how safe it is and how well it helps your body fight off the Chikungunya virus, which can make people very sick, especially during outbreaks, and it's looking for volunteers to help find the best dose for protection.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Najit Technologies, INC. NIH-funded |
| Lab location | 1 site (Beaverton, UNITED STATES) |
| Project start | July 1, 2020 |
| Project end | June 30, 2027 |
| Funding year | 2024 |
| Award (this year) | $986,133 |
| NIH project number | 4U44AI152995-02 |
| Project ID | NIH-11009620 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include healthy adults aged 21 and older who are interested in participating in vaccine trials.
✕Less likely to help
Patients who are currently infected with Chikungunya virus or have severe underlying health conditions may not benefit from this research.
What this research studies
This research investigates a new vaccine called HydroVax-CHIKV designed to protect against the Chikungunya virus, which can cause severe illness and has led to significant outbreaks globally. The study will involve a double-blind, randomized, placebo-controlled Phase 1 trial to assess the safety and immune response generated by the vaccine in participants. By using a peroxide-inactivated virus, the vaccine aims to provide a safe option for immunization, particularly for vulnerable populations. Participants will receive different doses to determine the most effective and safe level of vaccination.
Why it matters
Potential benefit: If successful, this research could lead to a safe and effective vaccine that protects against Chikungunya virus infections.
How similar studies have gone: While there has been significant interest in developing vaccines for Chikungunya, this specific approach using peroxide-inactivated virus is novel and has not been widely tested in clinical settings.
Where this research is happening
-
Najit Technologies, INC.
Beaverton, United States Active
Researchers
- Principal investigator: Amanna, Ian James — Najit Technologies, INC.
- Study coordinator: Amanna, Ian James
Related research
Other NIH-funded projects on the same topics.
-
HydroVax-CHIKV: a first-in-human vaccine against chikungunya for adults and at-risk groups
A first-in-human phase I trial tests a new inactivated chikungunya vaccine to see if it is safe and prompts an immune response in adults.
-
HydroVax-CHIKV: an inactivated chikungunya vaccine for adults
A new inactivated chikungunya vaccine being given to healthy adults to check safety and immune response.
-
A new vaccine for yellow fever that is safe for everyone.
This study is testing a new yellow fever vaccine called HydroVax-YFV to see if it's safe and effective for people who can't get the usual vaccine, like infants, pregnant women, and older adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.